INmune Bio Inc. is a clinical-stage biotechnology company dedicated to enhancing the innate immune system to combat diseases, particularly focusing on neurologic disorders and specific cancers. The company is developing first-in-class therapies that aim to maximize therapeutic benefits while ensuring patient safety. Their clinical development strategy emphasizes aligning the mechanism of action of their drugs with the biological characteristics of the patient population, utilizing relevant outcome metrics to prioritize patient benefits. This approach is reflected in their ongoing clinical trials, such as the MINDFuL study, which investigates the effects of XPro™ on early Alzheimer's disease, and the CaRe Prostate study, which evaluates INKmune therapy for metastatic castration-resistant prostate cancer.

The technologies employed by INmune Bio include innovative therapeutic agents like XPro1595, which selectively inhibits soluble tumor necrosis factor (TNF) to modulate immune responses and reduce neuroinflammation. This mechanism is particularly relevant in conditions such as Alzheimer's disease and various cancers, where TNF plays a critical role in disease progression. Additionally, INmune Bio is exploring the potential of INB03, an immune checkpoint inhibitor designed to reprogram macrophage polarization and enhance immune responses against tumors. Through these advanced therapeutic strategies, INmune Bio aims to restore immune function and improve patient outcomes in challenging disease states.

United States

INmune Bio Inc. is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer. INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. By controlling residual disease, patients may live longer. Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells’ ability to eliminate residual disease.

Media coverage provided for informational purposes only and third party links provided as a resource. INmune Bio does not control the content of third parties. XPro1595, Quellor, LIVNate, INB03, INKmune and other drug candidates, have not yet been shown to be safe or effective, and has not been approved by any regulatory body.

Cancer

Central Nervous System (CNS)

Immune System Diseases

Nervous System Diseases

Psychological Diseases

INmune Bio

Recessive dystrophic epidermolysis bullosa

CORDStrom

Major depressive disorder

Mental health

Treatment Resistant Depression

XPro1595 is a next-generation inhibitor of tumor necrosis factor (TNF) that acts differently than currently existing TNF inhibitors in that it neutralizes soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro1595 could have substantial beneficial effects in patients with neurologic disease by decreasing neuroinflammation.&nbsp;

XPro1595 (XPro™) (pegipanermin fr)

Breast cancer

Gastric cancer

HER2-expressing cancers

Pancreatic cancer

Triple-negative breast cancer

INB03 is a novel, second-generation TNF inhibitor that works by a Dominant Negative technology.&nbsp; INB03 is a PEGylated protein therapeutic that is administered as a once-weekly subcutaneous injection similar to an insulin shot.&nbsp; INB03 is not an antibody.&nbsp; INB03 neutralizes soluble TNF without affecting any other parts of TNF biology, allowing for more precise targeting.&nbsp; INB03 is differentiated from first-generation, approved TNF inhibitors that are used to treat autoimmune disorders such as rheumatoid arthritis.&nbsp; These first-generation TNF inhibitors are contra-indicated in patients with cancer because they cause immunosuppression, a side effect that could worsen the cancer.

INB03 + trastuzumab-deruxtecan

Alzheimer's disease

XPro1595 is a next-generation inhibitor of tumor necrosis factor (TNF) that acts differently than currently existing TNF inhibitors in that it neutralizes soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro1595 could have substantial beneficial effects in patients with Alzheimer’s disease by decreasing neuroinflammation.&nbsp;

XPro1595 (XPro™)

Castration-resistant prostate cancer

Prostate cancer

INKmune is an NK cell targeted therapy that is not an NK cell&nbsp;per se&nbsp;but a pharmaceutical-grade, replication-incompetent human tumor cell line which conjugates to resting NK cells in the patient and delivers multiple, essential priming signals, akin to treatment with at least three cytokines in combination; it is a&nbsp;pseudokine. These INKmune-generated tumor-primed NK (TpNK) cells can lyse a wide variety of NK-resistant tumors including leukemias, lymphomas, myeloma and solid tumors including prostate, renal cell, ovarian, nasopharyngeal, lung and breast cancer. INKmune therapy does not require any type of conditioning, pre-medication or cytokine support.&nbsp;

INKmune™

COVID-19

Quellor™ is a next-generation inhibitor of tumor necrosis factor (TNF) that is different from currently existing non-selective TNF inhibitors. Quellor™ neutralizes soluble TNF (sTNF) using a novel dominant-negative biology that importantly does not affect trans-membrane TNF (tmTNF) or TNF receptors. Currently approved TNF inhibitors block both sTNF and tmTNF. Quellor™ could have beneficial effects in patients with immune mediated complications from COVID-19 by decreasing inflammation and inflammatory immune complications such as&nbsp;<a href="https://www.globenewswire.com/Tracker?data=kFS-9A8aeuaE6Ty6axr7kwl7Msaifjr-44MtGYoWSVra2iV57QZQX21Fqy94i4Dpy0SucZZt_dwm7xXrVcN4DNXDlRN5mrSYkufG6jSObr01Asgoc_hChJKBsEMVyMsjw_lnc5eg28Pw7i-8AKoOJxcP9SyhFM4UlLzDpaSGa-UqPP2xvzLNvNJqPBnq1t6Y" rel="nofollow" target="_blank" title="endothelial cell activation">endothelial cell activation</a>, a potentially important cause of COVID-19-related coagulopathy which is increasingly blamed for end-organ dysfunction in lungs, kidneys, heart and brain. By targeting only sTNF, Quellor™ does not cause immunosuppression that is typical of most anti-cytokine therapies including currently approved anti-TNF and anti-IL-6 therapies. This may be an advantage when treating patients with a life-threatening viral infection.

Quellor™ 

Liver disease

NASH-induced significant or severe fibrosis

INmune Bio believes that targeting the innate immune inflammation that &nbsp;causes the three inflammatory cycles with LIVNate, the name of our &nbsp;DN-TNF drug for treating liver disease, may be an effective therapy for &nbsp;NASH.&nbsp; Based in animal data in models of NAFLD (nonalcoholic fatty liver &nbsp;disease) and NASH, treatment with LIVNate decreases at least 6 &nbsp;important elements in the pathophysiology of NASH (please refer to NASH &nbsp;slides in corporate presentation):
<ol class="font_7">
 <li>decreases insulin resistance</li>
 <li>decreases inflammation caused by inflamed adipocytes in peripheral fat and mesenteric adipocytes</li>
 <li>decreases intestinal leak by promoting translation of the proteins responsible for the integrity of intestinal tight junctions</li>
 <li>decreases steatosis or fatty infiltrate of the liver that promotes lipotoxicity</li>
 <li>decreases liver inflammation that causes hepatocyte ballooning the sign of “sick” hepatocytes</li>
 <li>decreases liver fibrosis, the cause of cirrhosis</li>
</ol>

INmune Bio

Company Details